Showing 1 - 10 of 23 Heart and Blood Diseases

Status: Enrolling

Investigator: Dipan Shah

Study Coordinator: Bevin Lopez

Phone: 346.238.5810

This study is designed to evaluate the efficacy of Dotarem enhanced MRI compared to Magnevist and Gadavist enhanced MRI in identifying myocardial infarct. Eighty patients will be recruited for this study. Patients with known CAD and undergoing c ... Read more >

Status: Open Not Enrolling

Investigator: Sherif Nagueh

Study Coordinator: Nirali Patel

Phone: 713.441.2116

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting ... Read more >

Status: Enrolling

Investigator: Neal Kleiman

Study Coordinator: Deena Victor

Phone: 713.441.4536

Brief Summary: To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR. Detailed Descripti ... Read more >

Status: Open Not Enrolling

Investigator: Michael Reardon

Study Coordinator: Iris Alanis

Phone: 713.441.6548

Brief Summary: Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortalit ... Read more >

Status: Enrolling

Investigator: Miguel Valderrabano

Study Coordinator: Chinwe Ngumezi

Phone: 713.441.6548

Brief Summary: The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-t ... Read more >

Status: Open Not Enrolling

Investigator: Sachin Goel

Study Coordinator: Tia McGaughy

Phone: 346.238.4576

Brief Summary: Study to evaluate the feasibility, safety and performance of the HighLife trans-septal Transcatheter Mitral Valve in patients with moderate-severe and severe mitral regurgitation who are at high risk for surgical treatment. In ... Read more >

Status: Open Not Enrolling

Investigator: Mahwash Kassi

Study Coordinator: Jan-Michael Ragunton

Phone: 713.441.9837

To evaluate the efficacy of eplontersen compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com. ... Read more >

Status: Enrolling

Investigator: Sachin Goel

Study Coordinator: Deena Victor

Phone: 713.441.4536

Brief Summary: The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral regurgitation = Grade III in whom transcatheter therapy i ... Read more >

Status: Open Not Enrolling

Investigator: Neal Kleiman

Study Coordinator: Deena Victor

Phone: 713.441.4536

The primary objective of the study is to evaluate the safety and effectiveness of the Medtronic CoreValve® System (MCS) in a subset of subjects excluded from the U.S. Extreme Risk Pivotal Trial population due to one or more additional co-morbidi ... Read more >

Status: Open Not Enrolling

Investigator: Miguel Valderrabano

Study Coordinator: Chinwe Ngumezi

Phone: 713.441.6548

Brief Summary: The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the DiamondTemp Ablation System for the treatment of drug refractory, symptomatic persistent atrial fibrillation in patients. Detailed Desc ... Read more >

Status: Enrolling

Investigator: Neal Kleiman

Study Coordinator: Deena Victor

Phone: 713.441.4536

Brief Summary: To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surger ... Read more >

Status: Enrolling

Investigator: Neal Kleiman

Study Coordinator: Deena Victor

Phone: 713.441.4536

Brief Summary: Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, symptomatic AS. Detailed Description: Multi-center, international, prospective, randomized ... Read more >

Status: Open Not Enrolling

Investigator: Alpesh Shah

Study Coordinator: Iris Alanis

Phone: 713.441.6548

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided percutaneous coronary intervention (PCI) in patients with multi ... Read more >

Status: Open Not Enrolling

Investigator: Sherif Nagueh

Study Coordinator: Nirali Patel

Phone: 713.441.2116

Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease and the most frequent cause of sudden cardiac death (SCD) in the young. It is characterized by unexplained left ventricular hypertrophy (LVH), diffuse and patchy fibros ... Read more >

Status: Open Not Enrolling

Investigator: Mahwash Kassi

Study Coordinator: Jan-Michael Ragunton

Phone: 713.441.9837

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy. ... Read more >

Status: Enrolling

Investigator: Sachin Goel

Study Coordinator: Tia McGaughy

Phone: 346.238.4576

Brief Summary: The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve ha ... Read more >

Status: Open Not Enrolling

Investigator: Vivek Misra

Study Coordinator:

Phone:

he primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-da ... Read more >

Status: Enrolling

Investigator: David Chiu

Study Coordinator:

Phone:

A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours. ... Read more >

Status: Open Not Enrolling

Investigator: Neal Kleiman

Study Coordinator: Tia McGaughy

Phone: 346.238.4576

The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgic ... Read more >

Status: Enrolling

Investigator: Michael Reardon

Study Coordinator: Iris Alanis

Phone: 713.441.6548

Brief Summary: To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and ... Read more >

Status: Enrolling

Investigator: Neal Kleiman

Study Coordinator: Tia McGaughy

Phone: 346.238.4576

Brief Summary: Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device. Inclusion Criteria: Moderate to severe or severe symptomatic mitral regurgitation Loca ... Read more >

Status: Enrolling

Investigator: Stephen Little

Study Coordinator: Iris Alanis

Phone: 713.441.6548

Brief Summary: The primary objective of this trial is to demonstrate the safety and effectiveness of the TriClip device in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or ... Read more >

Status: Enrolling

Investigator: Sachin Goel

Study Coordinator: Tia McGaughy

Phone: 346.238.4576

Brief Summary: The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expan ... Read more >